[CLSTR]
< Back to all clusters
[HEALTH] · 2 sources

started · updated

Part of situation: Advancements in cancer immunotherapy and targeted treatments (2 clusters)

Verastem Oncology reports VS-7375 efficacy in KRAS G12D tumor trials

KRAS G12D inhibitor pancreatic cancer colorectal cancer non-small cell lung cancer clinical trial

Verastem Oncology has reported clinical results from its phase 1/2 TARGET-D 101 trial regarding VS-7375, an investigational oral KRAS G12D inhibitor. The drug demonstrated antitumor activity in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), metastatic colorectal cancer (CRC), and advanced non-small cell lung cancer (NSCLC).

In the pancreatic cancer cohort, patients receiving a 900 mg daily dose showed a confirmed objective response rate (ORR) of 50% in the second-line setting. For patients in the second-line and later setting, the ORR was 41%, with a disease control rate of 86%. The 6-month landmark progression-free survival and overall survival rates were 67% and 80%, respectively.

Verastem Oncology has reached an agreement with the FDA to proceed with a phase 3 clinical trial for VS-7375, focusing on first-line metastatic PDAC.

Entities

FDA · VS-7375 · Verastem Oncology

Sources

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors [www.cancernetwork.com]
Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript [seekingalpha.com]